Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (TIDE DME)
2016年10月26日 更新者:Novartis Pharmaceuticals
A Randomized, Single-blinded, Multicenter, Phase IV Study to Compare Systemic VEGF Protein Dynamics Following Monthly Intravitreal Injections of 0.5 mg Ranibizumab Versus 2 mg Aflibercept Until Study Week 12 in Patients With Visual Impairment Due to Diabetic Macular Edema
The purpose of the study is to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic VEGF protein levels in DME patients in a detailed time course.
研究概览
研究类型
介入性
阶段
- 第四阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Chemnitz、德国、09113
- Novartis Investigative Site
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Type 1 or Type 2 diabetes mellitus
- Visual impairment predominantly due to DME.
Exclusion Criteria:
- Stroke or myocardial infarction less than 3 months prior to screening.
- Presence of uncontrolled systolic blood pressure or diastolic blood pressure
- Renal failure requiring dialysis or renal transplant or renal insufficiency
- Untreated diabetes mellitus
- Use of any systemic anti-VEGF drugs
- Use of systemic or inhaled corticosteroids for at least 30 consecutive days within 3 months prior to screening.
- Women who are pregnant or breast feeding or who are menstruating and capable of becoming pregnant* and not practicing a medically approved method of contraception
For either eye:
- Any active periocular or ocular infection or inflammation
- Uncontrolled glaucoma
- Neovascularization of the iris or neovascular glaucoma
- History of treatment with any anti-angiogenic drugs
For study eye:
- Atrophy or fibrosis involving the center of the fovea at the time of screening or baseline.
- Cataract (if causing significant visual impairment), planned cataract surgery during the study period, vitrectomy, aphakia, glaucoma surgery, severe vitreous hemorrhage, rhegmatogenous retinal detachment, proliferative retinopathy or choroidal neovascularization or macular edema of any other cause than DME
- Irreversible structural damage within 0.5 disc diameter of the center of the macula
- Panretinal laser photocoagulation within 6 months prior to randomization.
- Focal/grid laser photocoagulation within 3 months prior to randomization.
- Any intraocular procedure (including cataract surgery, Yttrium-Aluminum-Garnet capsulotomy) within 3 months prior to baseline or anticipated within the next 6 months following
- Topical ocular corticosteroids administered for at least 30 consecutive days within 3 months prior to screening.
- Application of intravitreal corticosteroids in vitreous within 6 months prior to screening. Prior application of fluocinolonacetonid releasing implant in vitreous within 36 months prior to screening.
For fellow eye
- Retinal or choroidal neovascularization or macula edema of any cause
Other protocol-defined inclusion/exclusion criteria may apply.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Group 1
Monthly intravitreal injections of 0.5 mg ranibizumab
|
0.5 mg玻璃体内注射
其他名称:
|
|
实验性的:Group 2
Three monthly intravitreal injections of 2 mg aflibercept followed by three monthly intravitreal injections of 0.5 mg ranibizumab
|
0.5 mg玻璃体内注射
其他名称:
2毫克玻璃体内注射
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Systemic VEGF-A protein levels
大体时间:From baseline to study week 12
|
Systemic VEGF-A protein levels following monthly intravitreal injections of 0.5 mg ranibizumab versus 2 mg aflibercept (Area under the curve)
|
From baseline to study week 12
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Systemic VEGF-A protein levels
大体时间:From study week 12 to 24
|
Systemic VEGF-A protein levels in patients switching from monthly 2 mg aflibercept injections to monthly 0.5 mg ranibizumab compared to patients treated with 0.5 mg ranibizumab from baseline
|
From study week 12 to 24
|
|
Systemic VEGF-A levels
大体时间:From study week 12 to 24
|
Adjustment of systemic VEGF-A levels of patients switching from aflibercept to ranibizumab to levels comparable to baseline or to levels comparable as in patients treated from baseline with ranibizumab
|
From study week 12 to 24
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 研究主任:Novartis Pharmaceutical、Novartis Pharmaceuticals
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2015年10月1日
初级完成 (预期的)
2016年10月1日
研究完成 (预期的)
2016年10月1日
研究注册日期
首次提交
2014年10月2日
首先提交符合 QC 标准的
2014年10月2日
首次发布 (估计)
2014年10月7日
研究记录更新
最后更新发布 (估计)
2016年10月27日
上次提交的符合 QC 标准的更新
2016年10月26日
最后验证
2016年10月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.